Stratagene Asks Texas Judge to Reduce Damages In Invitrogen Case as Jury Award Eats Q2 Earnings | GenomeWeb
Stratagene is hoping that a US District Court judge in Texas will decrease the $7.8 million in damages a jury awarded to Invitrogen in a patent-infringement case, President and CEO Joe Sorge said during a conference call this week.
The Invitrogen case is one of several legal disputes in which Stratagene is embroiled and hopes to wrap up this year, either through final court rulings or settlements, according to Sorge.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.